论文部分内容阅读
为评价瘤内注射(131)~I 标记单抗对提高肿瘤放射免疫治疗效果的作用,用(125)~I 标记抗人结肠癌单抗 CL-3,测定与人结肠癌细胞系 LS174T 及人胃印戒细胞癌细胞系 KATOⅢ的结合率。用34只 LS174T 荷瘤裸鼠,在瘤内注射(131)~I-CL-3后1、3、5、17天进行体内分布与放射免疫显像,以腹腔注射及(131)~I-正常鼠 IgG 瘤内注射组作对照。结果:(131)~I-CL-3与LS174T 及 KATOⅢ细胞结合率达73%;荷瘤裸鼠的瘤/非瘤比值瘤内注射组比腹腔内注射组大2～7倍;每克组织结合注入量的百分数瘤内注射组比腹腔内注射组大2倍多,比(131)~I-IgG 瘤内注射组大5～7倍,且放射免疫显像图清晰。故瘤内注射是提高放射免疫治疗效果的重要途径。单抗标记物在瘤内的存留主要是免疫结合,而不是 IgG 的非特异结合。
To evaluate the effect of intratumoral injection of (131)-I-labeled monoclonal antibody on enhancing the radioimmunotherapy efficacy of tumors, the anti-human colon cancer monoclonal antibody CL-3 was labeled with (125)-I, and it was tested with human colon cancer cell line LS174T and humans. The binding rate of gastric signet-ring cell carcinoma cell line KATOIII. Thirty-four LS174T tumor-bearing nude mice were used for in vivo distribution and radioimmunoassay 1, 3, 5, and 17 days after intratumoral injection of (131)-I-CL-3 to intraperitoneal injection and (131) to I- The normal mouse IgG intratumoral injection group served as a control. RESULTS: The binding rate of (131)-I-CL-3 to LS174T and KATOIII cells was 73%. The tumor/nontumor ratio of tumor-bearing nude mice was 2-7 times larger than that of intraperitoneal injection group; The percentage of combined injections in the intratumoral injection group was more than two times greater than in the intraperitoneal injection group and 5 to 7 times larger than the (131) to I-IgG intratumoral injection group, and the radioimmunoimage was clear. Therefore, intratumoral injection is an important way to improve the effectiveness of radioimmunotherapy. The retention of monoclonal antibodies in tumors is mainly immunological binding, rather than non-specific binding of IgG.